Relafen 750, pharmacologically known as naproxen, represents a significant case study from a pharmacological pharmacy standpoint. The drug exhibits its pain-relieving effect primarily by inhibiting the activity of cyclooxygenase (COX) enzymes, specifically COX-2, thereby decreasing prostaglandin production . The selective inhibition of COX-2, compa